アブストラクト
| Title | 14. 肝細胞癌に対する治療薬の今後の展望 |
|---|---|
| Subtitle | 特集 肝細胞癌に対する薬物療法の進歩 |
| Authors | 古瀬純司 |
| Authors (kana) | |
| Organization | 杏林大学医学部腫瘍内科学教室 |
| Journal | 肝臓クリニカルアップデート |
| Volume | 6 |
| Number | 1 |
| Page | 85-90 |
| Year/Month | 2020 / 5 |
| Article | 報告 |
| Publisher | 医学図書出版 |
| Abstract | 「要旨」 肝細胞癌に対する薬物療法は, ソラフェニブによる標準治療が確立して以降, 血管新生阻害薬を中心に開発されてきた. 1次治療としてレンバチニブ, 2次以降としてレゴラフェニブ, ラムシルマブ, カボザンチニブの有効性が報告されている. 最近では免疫チェックポイント阻害薬が試みられ, アテゾリズマブ+ベバシズマブ併用療法による高い有効性が報告された. 現在, 抗PD-1/PD-L1阻害薬+血管新生阻害薬あるいは抗CTLA-4抗体薬による臨床試験が行われている. これらの新規治療法により, 肝細胞癌に対する治療戦略が大きく変わるものと期待される. |
| Practice | 臨床医学：内科系 |
| Keywords | 肝細胞癌, 血管新生阻害薬, 免疫チェックポイント阻害薬 |
- 全文ダウンロード： 従量制、基本料金制の方共に1,023円(税込) です。
参考文献
- 1) Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008
- 2) Kudo M, Finn RS, Qin S, et al: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391: 1163-1173, 2018
- 3) Bruix J, Qin S, Merle P, et al: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE): a randomised, double-blind, placebo-centrolled, phase 3 tria1. Lancet 389: 56-66, 2017
- 4) Abou-Alfa GK, Meyer T, Cheng AL, et al: Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 379: 54-63, 2018
- 5) Zhu AX, Park JO, Ryoo BY, et al: Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib(REACH): a randomised, deuble-blind, multicentre, phase 3 trial. Lancet Oncol 16: 859-870, 2015
残りの12件を表示する
- 6) Zhu AX, Kang YK, Yen CJ, et al: Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations(REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20: 282-296, 2019
- 7) Finn RS, Ryoo BY, Merle P, et al: Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEY-NOTE-240: a randomized, doubie-blind, phase III trial. J Clin Oncol 38: 193-202, 2020
- 8) Yau T, Park JW, Finn RS, et al: CheckMate 459: a randomized, multi-center phase III study of nivolumab(NIVO) vs sorafenib(SOR) as first-line(1L)treatment in patients(pts) with advanced hepatocellular carcinoma(aHCC). Ann Oncol 30: v874-875, 2019
- 9) Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372: 2509-2520, 2015
- 10) Le DT, Durham JN, Smith KN, et al: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357: 409-413, 2017
- 11) Schumacher TN, Schreiber RD: Neoantigens in cancer immunotherapy. Science 348: 69-74, 2015
- 12) Cheng AL, Qin S, Ikeda M, et al: IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab(atezo)+bevacizumab (bev)vs sorafenib(Sor)as first treatment(tx) for patients(pts)with unresectable hepatocellular carcinoma(HCC). Ann Oncol 30: ix186-187, 2019
- 13) Ogasawara S, Chiba T, Ooka Y, et al: Eflicacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology 87: 330-341, 2014
- 14) Arizumi T, Ueshima K Minami T, et al: Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization(TACE)refractory and intermediate-stage hepatocellular carcinoma. Liver Cancer 4: 253-262, 2015
- 15) Ohki T, Sato K, Yamagami M, et al: Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis. Clin Drug Investig 35: 751-759, 2015
- 16) Kudo M, Ueshima K, Chan S, et al: Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child-pugh a liver function: a proof-of-concept study. Cancers(Basel) 11: E1084, 2019
- 17) Kudo M, Ueshima K, Ikeda M, et al: Randomised, multicentre prospective trial of transarterial chemoembolisation(TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2019 [Epub ahead of print]
